Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Sep 27, 2021; 13(9): 1025-1038
Published online Sep 27, 2021. doi: 10.4240/wjgs.v13.i9.1025
Published online Sep 27, 2021. doi: 10.4240/wjgs.v13.i9.1025
Carbohydrate antigen 19-9 as a novel prognostic biomarker in distal cholangiocarcinoma
Tao Jiang, Shao-Cheng Lyu, Lin Zhou, Jing Wang, Han Li, Qiang He, Ren Lang, Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China
Author contributions: Jiang T and Lyu SC contributed to the conception and design; He Q and Lang R contributed to the administrative support; Zhou L and Lang R contributed to the provision of study materials or patients; Wang J and Li H contributed to the collection and assembly of data; Lyu SC, Wang J and Zhou L contributed to the data analysis and interpretation; All authors contributed to the manuscript writing and final approval of manuscript.
Supported by the Beijing Municipal Science & Technology Commission , No. Z181100001718164 ; and Capital’s Funds for Health Improvement and Research , No. CFH 2020-2-2036 .
Institutional review board statement: The study was approved by the Ethics Committee of Beijing Chaoyang Hospital, No. 2020-D.-301.
Informed consent statement: All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Data sharing statement: The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ren Lang, MD, PhD, Academic Fellow, Chief Doctor, Professor, Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, No. 8 Gongtinan Road, Chaoyang District, Beijing 100020, China. dr_langren@126.com
Received: March 1, 2021
Peer-review started: March 1, 2021
First decision: June 3, 2021
Revised: June 18, 2021
Accepted: August 19, 2021
Article in press: August 19, 2021
Published online: September 27, 2021
Peer-review started: March 1, 2021
First decision: June 3, 2021
Revised: June 18, 2021
Accepted: August 19, 2021
Article in press: August 19, 2021
Published online: September 27, 2021
Core Tip
Core Tip: Distal cholangiocarcinoma (DCC) is a rare malignant tumor in the digestive system and has a poor long-term prognosis. Curative resection is currently the best treatment for patients with DCC because of the lack of effective adjuvant therapies. Therefore, it is important to accurately predict the prognosis for formulating a reasonable treatment plan and avoiding unnecessary surgical trauma. Carbohydrate antigen 19-9 to serum γ-glutamyltransferase (CA19-9/GGT) ratio was adapted as an indicator to minimize the interference of obstructive jaundice CA19-9 level, to determine the strong associations between CA19-9/GGT and postoperative neoplasm recurrence and long-term outcome of DCC.